Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
TG Therapeutics

TG Therapeutics

A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases

TG Therapeutics is a publicly owned biopharmaceutical company headquartered in New York City, New York that was founded in 1993 by Michael Sean Weiss and Laurence H. Shaw. It focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's product pipeline has two therapies in clinical development, TG-1101 and TG-1202.

Products
TG-1101

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

TG-1202

TG-1202, also known as Umbrasilib, is an orally available PI3K delta inhibitor. It targets delta isoforms, which is believed to be important in the proliferation and survival of B-cell lymphocytes. Umbrasilib is in Phase 3 clinical development in combination with Ublituximab for patients with hematological malignancies.

TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19,TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.

TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.

The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

Preclinical studies

TG Therapeutics has several other products in its pipeline, which are at various stages of preclinical studies:

IRAK4

A key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's Macroglobulinemia, a rare B-cell cancer, as well as in some specific cases of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. IRAK4 is also key in regulating immune and inflammatory processes, suggesting that it may be useful in treating autoimmune related disorders.

Anti-PD-L1 & Anti-GITR

Anti-PD-L1 antibodies target programmed cell death ligand 1 (PD-L1). They are designed to block signals permitting effector T-cells to attack cancer. Anti-GITR antibodies target glucocorticoid-induced tumor necrosis factor receptor related protein (GITR). It has shown to amplify the antitumor immune responses in animal models. Pre-clinical research on therapies using a combination of these two antibodies have yielded positive results. The Anti-PD-L1 monoclonal antibody has been brought into Phase 1 of clinical development.

TG-1601

TG-1601 is a small molecule that binds to the epigenetic BET family of bromodomain-containing proteins and inhibits their binding to chromatin. It can increase the sensitivity of tumors to chemotherapy or specific standard of care by resetting the genome in tumor cells. TG-1601 is in pre-clinical development and is being tested in various IND-enabling studies.

TG-1701

TG-1701 is an orally available BTK inhibitor. Targeting BTk with small molecule inhibitors has demonstrated effectiveness as a treatment option for B-cell lymphomas and autoimmune diseases. The product is in Phase 1 clinical trials in China.

TG-1801

TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19, TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.

TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.

The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

Funding
Post-IPO Equity

On February 29, 2012 TG Therapeutics announced raising $25 million in Post-IPO capital.

Timeline

February 29, 2012
TG Therapeutics raises a $25,000,000 series A round.
May 18, 1993
TG Therapeutics was founded by Michael Weiss.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation at 60th American Society of Hematology Annual Meeting and Exposition

TG Therapeutics, Inc.

Web

News

Title
Author
Date
Publisher
Description
BioSpace
June 29, 2021
BioSpace
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD.
BioSpace
June 18, 2021
BioSpace
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Company's investigational once-daily, oral BTK inhibitor, presented today during the 16 th International Congress on Malignant Lymphoma (ICML).
Samsung Biologics
April 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization and TG Therapeutics (NASDAQ: TGTX),...
Mark Zipkin
April 16, 2021
BioSpace
TG Therapeutics is on track for a regulatory submission for anti-CD20 antibody ublituximab next quarter, on the back of new Phase III data showing it reduces relapses and brain lesions in patients with relapsing forms of multiple sclerosis (MS).
BioSpace
December 2, 2020
BioSpace
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigational once daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy, in Blood , the Journal of the American Society of Hematology. Michael S. Weiss, the Company's Executive Chairman and Chi
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.